A. Harzand, L. Tamariz, and J. Hare, Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition, Congestive Heart Failure, vol.3, issue.3, pp.179-182, 2012.
DOI : 10.1111/j.1751-7133.2011.00262.x

K. Ogino, M. Kato, Y. Furuse, and Y. Kinugasa, Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Crossover Preliminary Study, Circulation: Heart Failure, vol.3, issue.1, pp.73-81, 2010.
DOI : 10.1161/CIRCHEARTFAILURE.109.868604

W. Doehner and S. Anker, Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?, Heart, vol.91, issue.6, pp.707-709, 2005.
DOI : 10.1136/hrt.2004.057190

K. Hayashi, H. Kimata, and K. Obata, Xanthine Oxidase Inhibition Improves Left Ventricular Dysfunction in Dilated Cardiomyopathic Hamsters, Journal of Cardiac Failure, vol.14, issue.3, pp.238-244, 2008.
DOI : 10.1016/j.cardfail.2007.11.001

M. Kittleson and J. Hare, Xanthine oxidase inhibitors: an emerging class of drugs for heart failure, European Heart Journal, vol.26, issue.15, pp.1458-1460, 2005.
DOI : 10.1093/eurheartj/ehi321

C. Bergamini, M. Cicoira, A. Rossi, and C. Vassanelli, Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure, European Journal of Heart Failure, vol.51, issue.5, pp.444-452, 2009.
DOI : 10.1093/eurjhf/hfp042

C. Berry and J. Hare, Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications, The Journal of Physiology, vol.3, issue.3, pp.589-606, 2004.
DOI : 10.1113/jphysiol.2003.055913

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1664875

G. Lippi, M. Montagnana, M. Franchini, E. Favaloro, and G. Targher, The paradoxical relationship between serum uric acid and cardiovascular disease, Clinica Chimica Acta, vol.392, issue.1-2, pp.1-7, 2008.
DOI : 10.1016/j.cca.2008.02.024

D. Rothenbacher, A. Kleiner, and W. Koenig, Relationship between inflammatory cytokines and uric acid levels with adverse cardiovasular outcomes in patients with stable coronary heart disease, Plos One, vol.7, pp.1-8, 2012.

T. Kawai, M. Ohishi, Y. Takeya, and M. Onishi, Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients, Hypertension Research, vol.31, issue.11, pp.1087-1092, 2012.
DOI : 10.1038/hr.2012.99

E. Krishnan, . Mphil, A. Hariri, and O. Dabbous, Hyperuricemia and the Echocardiographic Measures of Myocardial Dysfunction, Congestive Heart Failure, vol.12, issue.3, pp.138-143, 2012.
DOI : 10.1111/j.1751-7133.2011.00259.x

P. Puddu, G. Puddu, E. Cravero, L. Vizioli, and A. Muscari, The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications, Journal of Cardiology, vol.59, issue.3, pp.235-242, 2012.
DOI : 10.1016/j.jjcc.2012.01.013

M. Alderman, Uric acid and cardiovascular risk, Current Opinion in Pharmacology, vol.2, issue.2, pp.126-130, 2002.
DOI : 10.1016/S1471-4892(02)00143-1

Y. Nozari and B. Geraiely, Correlation between the serum levels of uric acid and HS-CRP with the occurrence of early systolic failure of left ventricle following acute myocardial infarction, Acta Medica Iranica, vol.49, pp.531-535, 2011.

M. Kaya, H. Uyarel, M. Akpek, N. Kalay, and M. Ergelen, Prognostic Value of Uric Acid in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention, The American Journal of Cardiology, vol.109, issue.4, pp.486-491, 2012.
DOI : 10.1016/j.amjcard.2011.09.042

V. Trkulja and S. Car, On-admission serum uric acid predicts outcomes after acute myocardial infarction: systematic review and meta-analysis of prognostic studies, Croatian Medical Journal, vol.53, issue.2, pp.162-172, 2012.
DOI : 10.3325/cmj.2012.53.162

I. Miedema, M. Uyttenboogaart, M. Koch, B. Fremer, and J. Keyser, Lack of association between serum uric acid levels and outcome in acute ischemic stroke, Journal of the Neurological Sciences, vol.319, issue.1-2, pp.319-51
DOI : 10.1016/j.jns.2012.05.019

F. Malek, P. Parenica, and J. , Uric acid, allopurinol therapy, and mortality in patients with acute heart failure???results of the Acute HEart FAilure Database registry, Journal of Critical Care, vol.27, issue.6, pp.737-748, 2012.
DOI : 10.1016/j.jcrc.2012.03.011

S. Kivity, E. Kopel, E. Maor, and F. Abu-bachar, Association of Serum Uric Acid and Cardiovascular Disease in Healthy Adults, The American Journal of Cardiology, vol.111, issue.8, 2013.
DOI : 10.1016/j.amjcard.2012.12.034

M. Kanbay, M. Segal, and B. Afsar, The role of uric acid in the pathogenesis of human cardiovascular disease, Heart, vol.5, issue.11, pp.1-8, 2013.
DOI : 10.1136/heartjnl-2012-302535

H. Kim, H. Yoon, H. Park, and Y. Cho, Potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congest Heart Fail, 2012.

I. Gotsman, K. A. Lotan, C. Zwas, and D. , Changes in Uric Acid Levels and Allopurinol Use in Chronic Heart Failure: Association With Improved Survival, Journal of Cardiac Failure, vol.18, issue.9, pp.694-701, 2012.
DOI : 10.1016/j.cardfail.2012.06.528

A. Eisen, M. Benderly, U. Goldbourt, and M. Haim, Is Serum Uric Acid Level an Independent Predictor of Heart Failure Among Patients With Coronary Artery Disease?, Clinical Cardiology, vol.108, issue.2, pp.110-116, 2012.
DOI : 10.1002/clc.22083

P. Jeemon and D. Prabhakaran, Does uric acid qualify as an independent risk factor for cardiovascular mortality?, Clinical Science, vol.17, issue.4, pp.255-257, 2013.
DOI : 10.1371/journal.pgen.1000504

V. Mellin, I. M. Oudot, A. Vergely, C. Monteil, and C. , Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure, European Heart Journal, vol.26, issue.15, pp.1544-1550, 2005.
DOI : 10.1093/eurheartj/ehi305

A. Wu, J. Ghali, G. Neuberg, O. Connor, and C. , Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure, American Heart Journal, vol.160, issue.5, pp.928-961, 2010.
DOI : 10.1016/j.ahj.2010.08.006

S. Anker, W. Doehner, M. Rauchhaus, R. Sharma, and D. Francis, Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging, Circulation, vol.107, issue.15, pp.1991-1997, 2003.
DOI : 10.1161/01.CIR.0000065637.10517.A0

J. Hare and R. Johnson, Uric Acid Predicts Clinical Outcomes in Heart Failure: Insights Regarding the Role of Xanthine Oxidase and Uric Acid in Disease Pathophysiology, Circulation, vol.107, issue.15, pp.1951-1953, 2003.
DOI : 10.1161/01.CIR.0000066420.36123.35

L. Tamariz, A. Harzand, A. Palacio, and S. Verma, Uric Acid as a Predictor of All-Cause Mortality in Heart Failure: A Meta-Analysis, Congestive Heart Failure, vol.12, issue.1, pp.25-30, 2011.
DOI : 10.1111/j.1751-7133.2011.00200.x

I. Holme, A. H. Aastveit, N. Hammar, I. Jungner, and G. Walldius, Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417???734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS), Journal of Internal Medicine, vol.51, issue.Suppl. 1, pp.558-570, 2009.
DOI : 10.1111/j.1365-2796.2009.02133.x

B. Alaoui, T. Mezalek, H. Harmouche, M. Aouni, and A. Maaouni, La goutte : nouvelles recommandations, Espérance médicale, vol.17, pp.119-133, 2010.

J. Mcmurray, S. Adamopoulos, S. D. Anker, and . Auricchio, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, vol.33, pp.1787-1847, 2012.

H. Yamanaka, Essence of the revised Guideline for the management of hyperuricemia an gout, JMAJ, vol.55, pp.324-329, 2012.

G. Lippi, . Montagnana, M. Franchini, E. Favaloro, and G. Targher, The paradoxical relationship between serum uric acid and cardiovascular disease, Clinica Chimica Acta, vol.392, issue.1-2, pp.1-7, 2008.
DOI : 10.1016/j.cca.2008.02.024

G. Thanassoulis, J. Brophy, H. Richard, L. Pilote, and . Gout, Gout, Allopurinol Use, and Heart Failure Outcomes, Archives of Internal Medicine, vol.170, issue.15, pp.1358-1364, 2010.
DOI : 10.1001/archinternmed.2010.198

F. Leyva, S. D. Anker, I. F. Godsland, and M. Teixeira, Uric acid in chronic heart failure: a marker of chronic inflammation, European Heart Journal, vol.19, issue.12, pp.1814-1822, 1998.
DOI : 10.1053/euhj.1998.1188

W. Doehner, N. Schoene, M. Rauchhaus, and F. Leyva-leon, Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies, Circulation, vol.105, issue.22, pp.2619-2624, 2002.
DOI : 10.1161/01.CIR.0000017502.58595.ED

T. Bardin and A. Cohen-solal, Goutte et pathologies cardiovasculaires, Revue du Rhumatisme, vol.78, pp.129-133, 2011.
DOI : 10.1016/S1169-8330(11)70025-4

S. Rekhraj, S. Gandy, B. Szwejkwski, and A. Nadir, High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease, Journal of the American College of Cardiology, vol.61, issue.9, pp.926-932, 2013.
DOI : 10.1016/j.jacc.2012.09.066

J. George, E. Carr, J. Davies, J. Belch, and A. Struthers, High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid, Circulation, vol.114, issue.23, pp.2508-2516, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.651117

J. Hare, B. Mangal, J. Brown, C. Fisher, and R. Feudenberger, Impact of Oxypurinol in Patients With Symptomatic Heart Failure, Journal of the American College of Cardiology, vol.51, issue.24, pp.2301-2309, 2008.
DOI : 10.1016/j.jacc.2008.01.068

M. Lainscak, S. Haehling, and S. Anker, Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers, International Journal of Cardiology, vol.132, issue.3, pp.303-311, 2009.
DOI : 10.1016/j.ijcard.2008.11.149

R. Freudenberger, . Schwarz, J. Brown, and A. Moore, Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standart therapy in patients with NYHA class III-IV congestive heart failure, Drugs, vol.13, pp.1509-1516, 2004.

S. Haehling, S. Bode-boger, and J. M. Lobenhoffer, Elevated Levels of Asymmetric Dimethylarginine in Chronic Heart Failure: A Pathophysiologic Link Between Oxygen Radical Load and Impaired Vasodilator Capacity and the Therapeutic Effect of Allopurinol, Clinical Pharmacology & Therapeutics, vol.91, issue.4, pp.506-512, 2010.
DOI : 10.1016/0140-6736(92)93147-F

A. Shehab, R. Butler, R. Macfadyen, and A. Strutchers, A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure, British Journal of Clinical Pharmacology, vol.52, issue.SupplA, pp.329-334, 2001.
DOI : 10.1046/j.1365-2125.2001.01361.x

L. Spieker, F. Ruschitzka, T. Lûscher, and G. Noll, The management of hyperuricemia and gout in patients with heart failure, European Journal of Heart Failure, vol.294, issue.610, pp.403-410, 2002.
DOI : 10.1016/S1388-9842(02)00086-7

G. Nasr and C. Maurice, Allopurinol and global left myocardial function in heart failure patients, J Cardiov Disease Research, vol.1, pp.191-195

N. Engberding, S. Spiekermann, A. Schaefer, and A. Heineke, Allopurinol Attenuates Left Ventricular Remodeling and Dysfunction After Experimental Myocardial Infarction: A New Action for an Old Drug?, Circulation, vol.110, issue.15, pp.2175-2179, 2004.
DOI : 10.1161/01.CIR.0000144303.24894.1C

N. Jia, P. Dong, Y. Ying, C. Qian, and Q. Dai, Allopurinol Attenuates Oxidative Stress and Cardiac Fibrosis in Angiotensin II-Induced Cardiac Diastolic Dysfunction, Cardiovascular Therapeutics, vol.275, issue.2, pp.117-123, 2012.
DOI : 10.1111/j.1755-5922.2010.00243.x

O. J. Ekundayo, L. Dell-'italia, and P. W. Sanders, Association between hyperuricemia and incident heart failure among older adults: A propensity-matched study, International Journal of Cardiology, vol.142, issue.3, pp.279-287, 2010.
DOI : 10.1016/j.ijcard.2009.01.010

A. Reyes, The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure, European Journal of Heart Failure, vol.27, issue.Suppl. 2, pp.461-647, 2005.
DOI : 10.1016/j.ejheart.2004.03.020

A. Noman, D. Ang, S. Ogston, C. Lang, and A. Struthers, Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial, The Lancet, vol.375, issue.9732, pp.2161-67, 2010.
DOI : 10.1016/S0140-6736(10)60391-1

J. H. Park, J. Y. Hwang, and S. , Uric acid attenuates nitic oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells : a mechanism for uric acid-induced cardiovascular desease development, Nitric Oxide, 2013.

E. Dogan, T. Senol, and A. Bayram, Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopatic dilated cardiomyopathy, Canadian Journal of Cardiology, vol.28, pp.721-727, 2012.

S. Baldasseoni, R. Urso, . Maggioni, and F. Orso, Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: Data from the IN-CHF Registry, Nutrition, Metabolism and Cardiovascular Diseases, vol.22, issue.5, pp.442-448, 2012.
DOI : 10.1016/j.numecd.2010.08.007

A. Strasak, E. Ruttman, and L. Brant, Serum Uric Acid and Risk of Cardiovascular Mortality: A Prospective Long-Term Study of 83 683 Austrian Men, Clinical Chemistry, vol.54, issue.2, pp.273-284, 2007.
DOI : 10.1373/clinchem.2007.094425

G. Jacob and A. Struthers, The role of urate and xanthine oxidase inhibitors in cardiovascular disease, Cardiovascular Therapeutics, vol.26, pp.59-64, 2008.

H. Cingolani, . Faha, and J. Plastino, The Effect of Xanthine Oxidase Inhibition Upon Ejection Fraction in Heart Failure Patients: La Plata Study, Journal of Cardiac Failure, vol.12, issue.7, pp.491-498, 2006.
DOI : 10.1016/j.cardfail.2006.05.005

A. D. Gavin and A. Struthers, Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure, Heart, vol.91, issue.6, pp.749-753, 2005.
DOI : 10.1136/hrt.2004.040477

W. Doehner and S. Anker, Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?, Heart, vol.91, issue.6, pp.707-709, 2005.
DOI : 10.1136/hrt.2004.057190

M. Cicoira, L. Zanolla, and A. Rossi, Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy, American Heart Journal, vol.143, issue.6, pp.1107-1118, 2002.
DOI : 10.1067/mhj.2002.122122

S. Arora, P. Aukrust, T. Ueland, and K. Broch, Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality, European Journal of Heart Failure, vol.68, issue.10, pp.1005-1013, 2009.
DOI : 10.1093/eurjhf/hfp115

URL : http://eurjhf.oxfordjournals.org/cgi/content/short/11/10/1005

M. Kittelson, V. Bead, M. Fradley, S. John, M. Champion et al., Elevated Uric Acid Levels Predict Allograft Vasculopathy in Cardiac Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.26, issue.5, pp.498-503, 2007.
DOI : 10.1016/j.healun.2007.01.039

N. Antonio, D. Prieto, and M. J. Antunes, Uric acid: a prognostic marker not only before but also after heart transplantation???, European Journal of Cardio-Thoracic Surgery, vol.38, issue.2, pp.187-191, 2010.
DOI : 10.1016/j.ejcts.2010.01.018

D. Misra, Y. Zhu, and Y. Zhang, The Independent Impact of Congestive Heart Failure Status and Diuretic Use on Serum Uric Acid Among Men with a High Cardiovascular Risk Profile: A Prospective Longitudinal Study, Seminars in Arthritis and Rheumatism, vol.41, issue.3, pp.471-476, 2011.
DOI : 10.1016/j.semarthrit.2011.02.002

A. Rosenbaum, S. Duval, S. Adatya, M. Salman, R. John et al., The effect of continuous left ventricular assist device implantation on serum uric acid levels, J Card, vol.4, pp.4291-4293, 2013.

C. Perel, F. Chin, P. Tuppin, N. Danchin, A. F. Juillière et al., Taux de patients hospitalisés pour insuffisance cardiaque en, France. Bull Epidemiol Hebd, vol.41, pp.466-70, 2002.

L. Clarson, P. Chandratre, S. Hider, C. Heneghan, J. Belcher et al., Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis, European Journal of Preventive Cardiology, vol.28, issue.3, pp.1-9, 2013.
DOI : 10.1016/S0895-4356(00)00242-0

U. Ekelund, R. Harrison, and O. Shokek, Intravenous Allopurinol Decreases Myocardial Oxygen Consumption and Increases Mechanical Efficiency in Dogs With Pacing-Induced Heart Failure, Circulation Research, vol.85, issue.5, pp.437-482, 1999.
DOI : 10.1161/01.RES.85.5.437

J. Zweier, R. Broderick, and P. Kuppusamy, Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation, J Biol Chem, vol.269, pp.24156-62, 1994.

P. Ferdinandy, D. Panas, and R. Schulz, Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts, Am J Physiol, vol.276, pp.1861-1868, 1999.

M. Can, S. Wagner, and L. Maier, Role of oxidants on calcium and sodium movement in healthy and disease cardiac myocytes, J Free Radical Biology and Med, vol.63, pp.338-349, 2013.

M. Pall, The NO/ONOO-Cycle as the Central Cause of Heart Failure, International Journal of Molecular Sciences, vol.14, issue.11, pp.22274-22330, 2013.
DOI : 10.3390/ijms141122274

L. Tang, H. Wang, and M. Ziolo, Targeting NOS as a therapeutic approach for heart failure, Pharmacology & Therapeutics, vol.142, issue.3, 2014.
DOI : 10.1016/j.pharmthera.2013.12.013

H. Huang, B. Huang, Y. Li, and Y. Huang, Uric acid and risk of heart failure: a systematic review and meta-analysis, European Journal of Heart Failure, vol.343, issue.737, pp.15-24, 2014.
DOI : 10.1093/eurjhf/hft132